National Institute of Mental Health; Notice of Closed Meeting, 14688-14689 [2020-05094]
Download as PDF
<![CDATA[
14688
Federal Register / Vol. 85, No. 50 / Friday, March 13, 2020 / Notices
Contact Person: Rebecca G. Baker, Ph.D.,
Office of the Director, National Institutes of
Health, 1 Center Drive, Room 103A,
Bethesda, MD 20892, (301) 402–1994,
Rebecca.baker@nih.gov.
This notice is being published less than 15
days prior to the meeting due to the timing
limitations imposed by the program.
Any interested person may file written
comments with the committee by forwarding
the statement to the Contact Person listed on
this notice. The statement should include the
name, address, telephone number and when
applicable, the business or professional
affiliation of the interested person.
In the interest of security, NIH has
instituted stringent procedures for entrance
onto the NIH campus. All visitor vehicles,
including taxicabs, hotel, and airport shuttles
will be inspected before being allowed on
campus. Visitors will be asked to show one
form of identification (for example, a
government-issued photo ID, driver’s license,
or passport) and to state the purpose of their
visit.
Information is also available on the Office
of the Director for the NIH HEAL Initiative
home page: https://www.nih.gov/researchtraining/medical-research-initiatives/healinitiative where an agenda and any
additional information for the meeting will
be posted when available.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.853, Clinical Research
Related to Neurological Disorders; 93.854,
Biological Basis Research in the
Neurosciences, National Institutes of Health,
HHS)
Dated: March 9, 2020.
Tyeshia M. Roberson,
Program Analyst, Office of Federal Advisory
Committee Policy.
[FR Doc. 2020–05098 Filed 3–12–20; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
jbell on DSKJLSW7X2PROD with NOTICES
National Institute of Diabetes and
Digestive and Kidney Diseases; Notice
of Closed Meeting
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended, notice is hereby given of the
following meeting.
The meeting will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
VerDate Sep<11>2014
18:16 Mar 12, 2020
Jkt 250001
Name of Committee: National Institute of
Diabetes and Digestive and Kidney Diseases
Special Emphasis Panel; Women’s Bladder
Health applications PLUS.
Date: April 16, 2020.
Time: 8:00 a.m. to 5:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: Doubletree Hotel Bethesda
(Formerly Holiday Inn Select), Conference
Room Auburn, 8120 Wisconsin Avenue,
Bethesda, MD 20814.
Contact Person: Ryan G. Morris, Ph.D.,
Scientific Review Officer, Review Branch,
Division of Extramural Activities, NIDDK,
National Institutes of Health, Room 7015,
6707 Democracy Boulevard, Bethesda, MD
20892–2542, (301) 594–4721, ryan.morris@
nih.gov.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.847, Diabetes,
Endocrinology and Metabolic Research;
93.848, Digestive Diseases and Nutrition
Research; 93.849, Kidney Diseases, Urology
and Hematology Research, National Institutes
of Health, HHS)
Dated: March 9, 2020.
Miguelina Perez,
Program Analyst, Office of Federal Advisory
Committee Policy.
[FR Doc. 2020–05112 Filed 3–12–20; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
National Institute on Deafness and
Other Communication Disorders;
Notice of Closed Meeting
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended, notice is hereby given of the
following meeting.
The meeting will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: National Institute on
Deafness and Other Communication
Disorders Special Emphasis Panel; Loan
Repayment Program Review.
Date: April 7, 2020.
Time: 11:00 a.m. to 12:00 p.m.
Agenda: To review and evaluate loan
Repayment Program.
Place: Neuroscience Center, Neuroscience
Building, 6001 Executive Blvd., Rm. 8359,
Rockville, MD 20852.
Contact Person: Sheo Singh, Ph.D.,
Scientific Review Officer, Scientific Review
PO 00000
Frm 00060
Fmt 4703
Sfmt 4703
Branch, Division of Extramural Activities,
6001 Executive Blvd., Room 8351, Bethesda,
MD 20892, (301) 496–8683, singhs@
nidcd.nih.gov.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.173, Biological Research
Related to Deafness and Communicative
Disorders, National Institutes of Health, HHS)
Dated: March 9, 2020.
Miguelina Perez,
Program Analyst, Office of Federal Advisory
Committee Policy.
[FR Doc. 2020–05111 Filed 3–12–20; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
National Institute of Mental Health;
Notice of Closed Meeting
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended, notice is hereby given of the
following meeting.
The meeting will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: National Institute of
Mental Health Special Emphasis Panel;
Mental Health Services.
Date: March 27, 2020.
Time: 2:00 p.m. to 3:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health,
Neuroscience Center, 6001 Executive Blvd.,
Rockville, MD 20852 (Telephone Conference
Call).
Contact Person: Aileen Schulte, Ph.D.,
Scientific Review Officer, Division of
Extramural Activities, National Institute of
Mental Health, NIH, Neuroscience Center,
6001 Executive Blvd., Room 6140, MSC 9608,
Bethesda, MD 20892–9608, 301–443–1225,
aschulte@mail.nih.gov.
This notice is being published less than 15
days prior to the meeting due to the timing
limitations imposed by the review and
funding cycle.
(Catalogue of Federal Domestic Assistance
Program No. 93.242, Mental Health Research
Grants, National Institutes of Health, HHS)
E:\FR\FM\13MRN1.SGM
13MRN1
Federal Register / Vol. 85, No. 50 / Friday, March 13, 2020 / Notices
Dated: March 9, 2020.
Melanie J. Pantoja,
Program Analyst, Office of Federal Advisory
Committee Policy.
[FR Doc. 2020–05094 Filed 3–12–20; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
Government-Owned Inventions;
Availability for Licensing
AGENCY:
National Institutes of Health,
HHS.
ACTION:
Notice.
The invention listed below is
owned by an agency of the U.S.
Government and is available for
licensing to achieve expeditious
commercialization of results of
federally-funded research and
development. Foreign patent
applications are filed on selected
inventions to extend market coverage
for companies and may also be available
for licensing.
FOR FURTHER INFORMATION CONTACT:
Peter Soukas, J.D., 301–594–8730;
peter.soukas@nih.gov. Licensing
information and copies of the patent
applications listed below may be
obtained by communicating with the
indicated licensing contact at the
Technology Transfer and Intellectual
Property Office, National Institute of
Allergy and Infectious Diseases, 5601
Fishers Lane, Rockville, MD 20852; tel.
301–496–2644. A signed Confidential
Disclosure Agreement will be required
to receive copies of unpublished patent
applications.
SUPPLEMENTARY INFORMATION:
Technology description follows.
SUMMARY:
jbell on DSKJLSW7X2PROD with NOTICES
Genomic Sequence of Avian
Paramyxovirus Type 2 and Uses
Thereof
Description of Technology
As a first step towards characterizing
the molecular genetics and pathogenesis
of avian paramyxovirus type 2 (APMV–
2), the biological activities and growth
characteristics of APMV–2 were
investigated. The present inventors
found that APMV–2 is different than
Newcastle Disease Virus (NDV, AMPV–
1) in several characteristics: (I) APMV–
2 does not require trypsin or allantoic
fluid to grow in cell culture; (II)
previous RNA–RNA hybridization
studies showed APMV–2 is genetically
different than NDV; (III) APMV–2 is the
only paramyxovirus serotype which
causes single-cell infection foci in cell
VerDate Sep<11>2014
18:16 Mar 12, 2020
Jkt 250001
culture, and does not induce cell fusion,
which is a hallmark of paramyxovirus
infection; (IV) APMV–2 does not kill
chicken embryos; and (V) APMV–2 does
not grow in the brain of chickens.
These results suggested that APMV–2
is significantly different biologically and
genetically from NDV. These differences
provide certain advantages over other
viruses considered for use as a vaccine,
as a virus vector, or as a therapeutic. For
example, unlike the current NDV
vaccine such as LaSota and Hitchner B1
that can cause disease due to reversion
to virulence, since AMPV–2 is not an
agricultural pathogen, it is not a concern
for the poultry industry. Unlike many
strains of NDV, APMV–2 is not a Select
Agent.
However, in order to develop a
recombinant APMV–2 virus for use as a
vector, vaccine, or cancer therapy, the
complete genome sequence was needed,
and a reverse genetic system needed to
be developed. Sequence analysis proved
to be difficult since primers based on
NDV were not useful because the two
viruses are genetically different.
Therefore, different strategies had to be
used for primer design, including the
design and testing of consensus primers
from other paramyxoviruses, primers
based on gene start and gene end
sequences of other paramyxoviruses,
and primer walking.
This invention covers the complete
genomic sequence of avian
paramyxovirus type 2, strains Yucaipa,
England, Kenya and Bangor. The
genomic sequence of strain Yucaipa was
used to develop a reverse genetic system
for AMPV–2. This produced cDNAderived AMPV–2 with the same
properties as biologically-derived
AMPV–2, confirming the authenticity of
the genomic sequence. The sequence
and reverse genetic system are useful for
production of recombinant infective
virus, a virus vector, for vaccine
development and for therapeutic
compositions. The sequences are also
useful for development of viral
diagnostics. The recombinant APMV–2
was used to express a foreign antigen,
the green fluorescent protein (GFP), and
can be used as a vaccine vector.
Recombinant APMV–2 can also be used
in cancer treatment, similar to NDV.
This technology is available for
licensing for commercial development
in accordance with 35 U.S.C. 209 and 37
CFR part 404, as well as for further
development and evaluation under a
research collaboration.
Potential Commercial Applications
• Viral therapeutics
• Viral diagnostics
• Vaccine research
PO 00000
Frm 00061
Fmt 4703
Sfmt 4703
14689
Competitive Advantages
• Ease of manufacture
• Low-cost vaccine
• Adjuvants unnecessary
Development Stage
• In vivo data assessment (animal)
Inventors: Siba Samal (EM), Peter
Collins (NIAID).
Intellectual Property: HHS Reference
No. E–019–2018–0—U.S. Provisional
Application No. 61/218,851, filed June
19, 2009, HHS Reference No. E–019–
2018–1—U.S. Patent Application No.
12/803165, filed June 21, 2010, now
U.S. Patent No. 9,937,196.
Licensing Contact: Peter Soukas, J.D.,
301–594–8730; peter.soukas@nih.gov.
Collaborative Research Opportunity:
The National Institute of Allergy and
Infectious Diseases is seeking statements
of capability or interest from parties
interested in collaborative research to
further develop, evaluate or
commercialize for development of a
vaccine for respiratory or other
infections. For collaboration
opportunities, please contact Peter
Soukas, J.D., 301–594–8730;
peter.soukas@nih.gov.
Dated: March 2, 2020.
Wade W. Green,
Acting Deputy Director, Technology Transfer
and Intellectual Property Office, National
Institute of Allergy and Infectious Diseases.
[FR Doc. 2020–05146 Filed 3–12–20; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
Submission for OMB Review; 30-Day
Comment Request; Generic Clearance
for NIH Citizen Science and
Crowdsourcing Projects (Office of the
Director)
AGENCY:
National Institutes of Health,
HHS.
ACTION:
Notice.
In compliance with the
Paperwork Reduction Act of 1995, the
National Institutes of Health (NIH) has
submitted to the Office of Management
and Budget (OMB) a request for review
and approval of the information
collection listed below.
DATES: Comments regarding this
information collection are best assured
of having their full effect if received
within 30-days of the date of this
publication.
SUMMARY:
Written comments and/or
suggestions regarding the item(s)
ADDRESSES:
E:\FR\FM\13MRN1.SGM
13MRN1
]]>Agencies
[Federal Register Volume 85, Number 50 (Friday, March 13, 2020)]
[Notices]
[Pages 14688-14689]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2020-05094]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health
National Institute of Mental Health; Notice of Closed Meeting
Pursuant to section 10(d) of the Federal Advisory Committee Act, as
amended, notice is hereby given of the following meeting.
The meeting will be closed to the public in accordance with the
provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5
U.S.C., as amended. The grant applications and the discussions could
disclose confidential trade secrets or commercial property such as
patentable material, and personal information concerning individuals
associated with the grant applications, the disclosure of which would
constitute a clearly unwarranted invasion of personal privacy.
Name of Committee: National Institute of Mental Health Special
Emphasis Panel; Mental Health Services.
Date: March 27, 2020.
Time: 2:00 p.m. to 3:00 p.m.
Agenda: To review and evaluate grant applications.
Place: National Institutes of Health, Neuroscience Center, 6001
Executive Blvd., Rockville, MD 20852 (Telephone Conference Call).
Contact Person: Aileen Schulte, Ph.D., Scientific Review
Officer, Division of Extramural Activities, National Institute of
Mental Health, NIH, Neuroscience Center, 6001 Executive Blvd., Room
6140, MSC 9608, Bethesda, MD 20892-9608, 301-443-1225,
[email protected].
This notice is being published less than 15 days prior to the
meeting due to the timing limitations imposed by the review and
funding cycle.
(Catalogue of Federal Domestic Assistance Program No. 93.242, Mental
Health Research Grants, National Institutes of Health, HHS)
[[Page 14689]]
Dated: March 9, 2020.
Melanie J. Pantoja,
Program Analyst, Office of Federal Advisory Committee Policy.
[FR Doc. 2020-05094 Filed 3-12-20; 8:45 am]
BILLING CODE 4140-01-P
